Advancements in Genetic Testing and Tumor Profiling for Uveal Melanoma Management |Derek J Maetzold, CEO, Castle Biosciences Inc. 00:10:00

Share On Facebook Share On Twitter

In a comprehensive interview, the CEO discusses the evolution of genetic testing and tumor profiling for uveal melanoma, highlighting the significance of specific gene mutations in predicting metastatic risk and guiding treatment decisions.

Recent Videos